Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H42N2O2S2 |
| Molecular Weight | 454.732 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 2 |
SHOW SMILES / InChI
SMILES
CC1=C(CCO)SC=[N+]1CCCCCCCCCCCC[N+]2=CSC(CCO)=C2C
InChI
InChIKey=UZPXHZIQHWKNPF-UHFFFAOYSA-N
InChI=1S/C24H42N2O2S2/c1-21-23(13-17-27)29-19-25(21)15-11-9-7-5-3-4-6-8-10-12-16-26-20-30-24(14-18-28)22(26)2/h19-20,27-28H,3-18H2,1-2H3/q+2
| Molecular Formula | C24H40N2O2S2 |
| Molecular Weight | 452.717 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Albitiazolium (SAR97276) is a clinical antimalarial candidate from a series of choline analogs designed to inhibit plasmodial phospholipid metabolism. Albitiazolium exerts powerful in vitro and in vivo antimalarial activities. Albitiazolium has been shown to have appropriate pharmacokinetic and safety parameters in humans and it was being tested in phase II clinical trials by Sanofi, with confirmed antimalarial activity in adult patients. However, Sanofi discontinued development of Albitiazolium.
Originator
Approval Year
Sample Use Guides
A total of 113 malaria patients received SAR97276. Adults were randomized to receive a single dose SAR97296 given either intramuscularly (IM) (0.18 mg/kg) or intravenously (IV) (0.14 mg/kg). If a single dose was not efficacious a second adult group was planned to test a three dose regimen administered IM once daily for 3 days. Single dose SAR97276 showed insufficient efficacy in adults (IM: 20 of 34 cured, 59%; and IV: 23/30 cured, 77%). The 3-day IM regimen showed acceptable efficacy in adults (27/30, 90%) but not in children (13/19, 68%).
Route of Administration:
Parenteral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:15:32 UTC 2023
by
admin
on
Fri Dec 15 17:15:32 UTC 2023
|
| Record UNII |
HKM715W3UT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11377023
Created by
admin on Fri Dec 15 17:15:32 UTC 2023 , Edited by admin on Fri Dec 15 17:15:32 UTC 2023
|
PRIMARY | |||
|
DTXSID10226315
Created by
admin on Fri Dec 15 17:15:32 UTC 2023 , Edited by admin on Fri Dec 15 17:15:32 UTC 2023
|
PRIMARY | |||
|
300000042526
Created by
admin on Fri Dec 15 17:15:32 UTC 2023 , Edited by admin on Fri Dec 15 17:15:32 UTC 2023
|
PRIMARY | |||
|
HKM715W3UT
Created by
admin on Fri Dec 15 17:15:32 UTC 2023 , Edited by admin on Fri Dec 15 17:15:32 UTC 2023
|
PRIMARY | |||
|
753439-46-2
Created by
admin on Fri Dec 15 17:15:32 UTC 2023 , Edited by admin on Fri Dec 15 17:15:32 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
